Kaos Capital in a letter to other Capricor Therapeutics shareholders called for “an immediate meeting, board change, and ...

The Phase 3 study is evaluating two doses of Novo’s Wegovy pill in people with obesity or overweight in combination with a ...

The accelerated greenlight for Ultragenyx’s gene therapy for glycogen storage disease has raised analyst expectations for ...

Melanoma was slower to recur in patients receiving Merck and Moderna's mRNA vaccine with Keytruda, supporting use of the ...

Regeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 ...

Despite coming away with an early victory over Eli Lilly in the oral obesity face-off, analysts don’t expect Novo Nordisk’s ...

After committing $2 billion to a new North Carolina facility to boost capacity for its next-gen obesity candidates, Roche's ...

If confirmed by the Senate, Heidi Overton—officially revealed Wednesday as President Donald Trump’s choice for FDA ...

Touting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers ...

Three fatalities occurring recently in China clinical trials have spurred two members of U.S. Congress to urge the FDA to ...

Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so ...

If Heidi Overton clears the Senate nomination process, analysts say she will have a tough job ahead to “restore ...